Recent Advancements in Prostate Catheters and Stents for Management of Benign Prostatic Hyperplasia.

IF 2.5 2区医学 Q2 UROLOGY & NEPHROLOGY

Current Urology Reports Pub Date : 2024-10-07 DOI:10.1007/s11934-024-01235-3

John Lama, Joshua Winograd, Alia Codelia-Anjum, Naeem Bhojani, Dean Elterman, Kevin C Zorn, Bilal Chughtai

{"title":"Recent Advancements in Prostate Catheters and Stents for Management of Benign Prostatic Hyperplasia.","authors":"John Lama, Joshua Winograd, Alia Codelia-Anjum, Naeem Bhojani, Dean Elterman, Kevin C Zorn, Bilal Chughtai","doi":"10.1007/s11934-024-01235-3","DOIUrl":null,"url":null,"abstract":"Purpose of review: The prevalence of benign prostatic hyperplasia (BPH) is rising, however, current treatment options present severe complications and limit patient's quality of life. Accordingly, advancements in prostatic catheter and stent designs for use in treating lower urinary tract symptoms (LUTS) in BPH patients have largely expanded in the past five years and we aim to provide an exhaustive summary of recent outcomes.Recent findings: The dual dilation and paxlitaxel eluting Optilume BPH Catheter System enhances promise in catheter-based treatments, providing the longest sustained increase in max urinary flow rate and decrease in post-void residual volume compared to alternative MISTs. Additionally, use of iTiND, along with recent advancements in temporary (EXIME, Prodeon Urocross) and permanent (Zenflow Spring, Butterfly, and ClearRing) stent designs, have demonstrated rapid, lasting, and low-cost LUTS relief with sustained sexual function. Minimally invasive solutions that offer in-office treatment, rapid symptom relief, shorter recovery times, and preservation of sexual function hold great promise in improving outcomes in managing BPH patients with LUTS.","PeriodicalId":11112,"journal":{"name":"Current Urology Reports","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Urology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11934-024-01235-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The prevalence of benign prostatic hyperplasia (BPH) is rising, however, current treatment options present severe complications and limit patient's quality of life. Accordingly, advancements in prostatic catheter and stent designs for use in treating lower urinary tract symptoms (LUTS) in BPH patients have largely expanded in the past five years and we aim to provide an exhaustive summary of recent outcomes.

Recent findings: The dual dilation and paxlitaxel eluting Optilume BPH Catheter System enhances promise in catheter-based treatments, providing the longest sustained increase in max urinary flow rate and decrease in post-void residual volume compared to alternative MISTs. Additionally, use of iTiND, along with recent advancements in temporary (EXIME, Prodeon Urocross) and permanent (Zenflow Spring, Butterfly, and ClearRing) stent designs, have demonstrated rapid, lasting, and low-cost LUTS relief with sustained sexual function. Minimally invasive solutions that offer in-office treatment, rapid symptom relief, shorter recovery times, and preservation of sexual function hold great promise in improving outcomes in managing BPH patients with LUTS.

查看原文本刊更多论文

用于治疗良性前列腺增生症的前列腺导管和支架的最新进展。

综述目的：良性前列腺增生症（BPH）的发病率正在上升，然而，目前的治疗方案存在严重的并发症，限制了患者的生活质量。因此，用于治疗良性前列腺增生症患者下尿路症状（LUTS）的前列腺导管和支架设计在过去五年中取得了长足的进步，我们旨在对最新成果进行详尽总结：双重扩张和紫杉醇洗脱 Optilume 良性前列腺增生导管系统提高了导管治疗的前景，与其他 MIST 相比，它能最持久地提高最大尿流率并减少排尿后残余尿量。此外，iTiND 的使用以及最近在临时性（EXIME、Prodeon Urocross）和永久性（Zenflow Spring、Butterfly 和 ClearRing）支架设计方面取得的进展，已证明能快速、持久、低成本地缓解 LUTS，并保持性功能。微创解决方案可提供诊室内治疗、快速缓解症状、缩短恢复时间并保持性功能，在改善良性前列腺增生症（BPH）LUTS 患者的治疗效果方面大有可为。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Urology Reports UROLOGY & NEPHROLOGY-

CiteScore

4.60

自引率

3.80%

发文量

期刊介绍： This journal intends to review the most important, recently published findings in the field of urology. By providing clear, insightful, balanced contributions by international experts, the journal elucidates current and emerging approaches to the care and prevention of urologic diseases and conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as benign prostatic hyperplasia, erectile dysfunction, female urology, and kidney disease. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.